A quantitative structure-activity relationship study on some sulfolanes and arylthiomethanes acting as HIV-1 protease inhibitors

被引:12
作者
Gupta, SP [1 ]
Babu, MS [1 ]
Sowmya, S [1 ]
机构
[1] Birla Inst Technol & Sci, Pilani 333031, Rajasthan, India
关键词
quantitative structure-activity relationship; HIV-1protease inhibitors; sulfolanes; arylthiomethanes;
D O I
10.1016/S0968-0896(98)00157-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A quantitative structure-activity relationship (QSAR) study on some sulfolanes and arylthiomethanes acting as human immunodeficiency virus-1 (HIV-1) protease inhibitors reveals that in the case of sulfolanes an octahydropyrindene ring and a five-membered 3(S)-sulfolane ring with a hydrophobic 2-substituent (cis to 3-substituent) will be crucial for the inhibition activity. The binding of a sulfolane, which is a nonpeptidic molecule, with the enzyme is shown to partly mimic the binding of a peptidic inhibitor. The 2-substituent is found to have strong hydrophobic interaction with the receptor. Similarly, in the case of arylthiomethanes, one of the substituents of the methane is found to have strong hydrophobic interaction with the enzyme, while the aryl substituent (4-hydroxy-6-phenyl-2-oxo-2H-pyran-3-yl) is assumed to be involved in the hydrogen bondings. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2185 / 2192
页数:8
相关论文
共 19 条
[1]  
Appelt Krzysztof, 1993, Perspectives in Drug Discovery and Design, V1, P23, DOI 10.1007/BF02171654
[2]   Molecular recognition of protein-ligand complexes: Applications to drug design [J].
Babine, RE ;
Bender, SL .
CHEMICAL REVIEWS, 1997, 97 (05) :1359-1472
[3]   PROTEIN DATA BANK - COMPUTER-BASED ARCHIVAL FILE FOR MACROMOLECULAR STRUCTURES [J].
BERNSTEIN, FC ;
KOETZLE, TF ;
WILLIAMS, GJB ;
MEYER, EF ;
BRICE, MD ;
RODGERS, JR ;
KENNARD, O ;
SHIMANOUCHI, T ;
TASUMI, M .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1978, 185 (02) :584-591
[4]   GENERATION AND CHARACTERIZATION OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) MUTANT RESISTANT TO AN HIV-1 PROTEASE INHIBITOR [J].
ELFARRASH, MA ;
KURODA, MJ ;
KITAZAKI, T ;
MASUDA, T ;
KATO, K ;
HATANAKA, M ;
HARADA, S .
JOURNAL OF VIROLOGY, 1994, 68 (01) :233-239
[5]   THE DEVELOPMENT OF CYCLIC SULFOLANES AS NOVEL AND HIGH-AFFINITY P(2) LIGANDS FOR HIV-1 PROTEASE INHIBITORS [J].
GHOSH, AK ;
LEE, HY ;
THOMPSON, WJ ;
CULBERSON, C ;
HOLLOWAY, MK ;
MCKEE, SP ;
MUNSON, PM ;
DUONG, TT ;
SMITH, AM ;
DARKE, PL ;
ZUGAY, JA ;
EMINI, EA ;
SCHLEIF, WA ;
HUFF, JR ;
ANDERSON, PS .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (08) :1177-1188
[6]  
GUPTA SP, 1998, UNPUB CHEM REV
[7]  
Hansch C., 1979, Substituent constants for correlation analysis in chemistry and biology
[8]   ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].
KOHL, NE ;
EMINI, EA ;
SCHLEIF, WA ;
DAVIS, LJ ;
HEIMBACH, JC ;
DIXON, RAF ;
SCOLNICK, EM ;
SIGAL, IS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690
[9]   DIASTEREOSELECTIVE SYN-EPOXIDATION OF 2-ALKYL-4-ENAMIDES TO EPOXYAMIDES - SYNTHESIS OF THE MERCK HIV-1 PROTEASE INHIBITOR EPOXIDE INTERMEDIATE [J].
MALIGRES, PE ;
UPADHYAY, V ;
ROSSEN, K ;
CIANCIOSI, SJ ;
PURICK, RM ;
ENG, KK ;
REAMER, RA ;
ASKIN, D ;
VOLANTE, RP ;
REIDER, PJ .
TETRAHEDRON LETTERS, 1995, 36 (13) :2195-2198
[10]  
MORIGUCHI I, 1976, CHEM PHARM BULL, V24, P1799